Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (141-150 of 264) with videos related to

Pageof 27
Sort By:
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Breast Cancer Research : BCR|February 24, 2019
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98Kevin H Kensler, Meredith M Regan, Yujing J Heng, et al.
Breast (Edinburgh, Scotland)|October 8, 2013
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Gini F Fleming, et al.
Future Oncology (London, England)|October 27, 2022
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain studyJosé Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
Breast Cancer Research : BCR|January 1, 2020
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrenceFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00Andrea Joaquin Garcia, Mattia Rediti, David Venet, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Breast Cancer Research and Treatment|August 9, 2011
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentationEmilia Montagna, Vincenzo Bagnardi, Nicole Rotmensz, et al.
Tumori|February 24, 2015
Nonrandomized comparison between concomitant and sequential chemoradiotherapy with anthracyclines in breast cancerMaria Cristina Leonardi, Anna Morra, Luigi Santoro, et al.
Pageof 27

Showing results (141-150 of 264) with videos related to

Sort By:
Pageof 27
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Breast Cancer Research : BCR|February 24, 2019
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98Kevin H Kensler, Meredith M Regan, Yujing J Heng, et al.
Breast (Edinburgh, Scotland)|October 8, 2013
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Gini F Fleming, et al.
Future Oncology (London, England)|October 27, 2022
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain studyJosé Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
Breast Cancer Research : BCR|January 1, 2020
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrenceFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00Andrea Joaquin Garcia, Mattia Rediti, David Venet, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Breast Cancer Research and Treatment|August 9, 2011
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentationEmilia Montagna, Vincenzo Bagnardi, Nicole Rotmensz, et al.
Tumori|February 24, 2015
Nonrandomized comparison between concomitant and sequential chemoradiotherapy with anthracyclines in breast cancerMaria Cristina Leonardi, Anna Morra, Luigi Santoro, et al.
Pageof 27